Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?

Menée à partir de données portant sur 206 patientes atteintes d'un cancer du sein après la ménopause, cette étude évalue l'effet, sur leurs fonctions cognitives, d'un traitement combinant ou non exémestane et tamoxifène

Résumé en anglais

Endocrine therapy (ET) is well-established as a treatment in hormone sensitive breast cancers which account for ~75% of breast cancers. Commonly used endocrine treatments include selective estrogen receptor modulators (e.g., tamoxifen), selective estrogen receptor degraders (e.g., fulvestrant), aromatase inhibitors (e.g., letrozole, anastrozole, exemestane) and ovarian function suppression (e.g., goserelin). There is strong evidence to support aromatase inhibitors (AIs) as the preferred adjuvant treatment for post-menopausal women with estrogen receptor positive (ER+) breast cancer, with reductions in breast cancer recurrence and mortality compared to women receiving tamoxifen.1 Options for pre-menopausal women are tamoxifen or an aromatase inhibitor with ovarian suppression